Evaluation of the dosimetry approaches in ablation treatment of thyroid cancer

Nalan Alan Selcuk, Turkay Toklu, Seval Beykan, Serife Ipek Karaaslan, Nalan Alan Selcuk, Turkay Toklu, Seval Beykan, Serife Ipek Karaaslan

Abstract

In this study, we aimed to evaluate dosimetric approaches in ablation treatment of Differentiated Thyroid Carcinoma (DTC) without interrupting the clinical routine. Prior to therapy, 10.7 MBq 131 I in average was orally given to 24 patients suffering from DTC. MIRD formalism was used for dosimetric calculations. For blood and bone marrow dosimetry, blood samples and whole-body counts were collected at 2, 24, 72, and 120 h after I-131 administration. For remnant tissue dosimetry, uptake measurements were performed at the same time intervals. To estimate the remnant volume, anterior and lateral planar gamma camera images were acquired with a reference source within the field of view at 24 h after I-131 administration. Ultrasound imaging was also performed. Treatment activities determined with the fixed activity method were administered to the patients. Secondary cancer risk relative to applied therapy was evaluated for dosimetric approaches. The average dose to blood and bone marrow were determined as 0.15 ± 0.04 and 0.11 ± 0.04 Gy/GBq, respectively. The average remnant tissue dose was 0.58 ± 0.52 Gy/MBq and the corresponding required activity to ablate the remnant was approximately 1.3 GBq of 131 I. A strong correlation between 24th-hour uptake and time-integrated activity coefficient values was obtained. Compared to fixed activity method, approximately five times higher secondary cancer risk was determined in bone marrow dosimetry, while the risk was about three times lower in lesion-based dosimetry.

Keywords: bone marrow dosimetry; remnant tissue dosimetry; thyroid ablation treatment.

© 2018 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine.

Figures

Figure 1
Figure 1
The relationship between 24th‐hour uptake value and TIAC.

References

    1. Werner SC, Ingbar SH, Braverman LE, Utiger RD. Werner & Ingbar's the Thyroid: A Fundamental and Clinical Text, 9th edn Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
    1. Roos DE, Smith JG. Randomized trials on radioactive iodine ablation of thyroid remnants for thyroid carcinoma – a critique. Int J Radiat Oncol Biol Phys. 1999;44:493–495.
    1. Sherman SI. Thyroid carcinoma. Lancet. 2003;361:501–511.
    1. Ramanna L, Waxman A, Brachman MB, Tanasescu DE, Sensel N, Braunstein GD. Evaluation of low‐dose ablation therapy in postsurgical thyroid cancer patients. Clin Nucl Med. 1985;10:791–795.
    1. Doi SA, Woodhouse NJ. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer. Clin Endocrinol (Oxf). 2000;52:763–773.
    1. Bal CS, Kumar A, Pant GS. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. J Clin Endocrinol Metab. 2004;89:1666–1673.
    1. Johansen K, Woodhouse NJ, Odugbesan O. Comparison of 1073 MBq and 3700 MBq iodine‐131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. J Nucl Med. 1991;32:252–254.
    1. Lassmann M, Reiners C, Luster M. Dosimetry and thyroid cancer: the individual dosage of radioiodine. Endocr Relat Cancer. 2010;17:R161–R172.
    1. Benua RS, Cicale NR, Sonenberg M, Rawson RW. Relation of radioiodine dosimetry to results and complications in treatment of metastatic thyroid cancer. Am J Roentgenol. 1962;87:171–182.
    1. Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med. 1983;309:937–941.
    1. Loevinger R, Berman M. A Revised Schema for Calculating the Absorbed Dose from Biologically Distributed Radionuclides, MIRD Pamphlet No. 1 Revised. New York, NY: The Society of Nuclear Medicine; 1976.
    1. Lassmann M, Hänscheid H, Chiesa C, Hindorf C, Flux G, Luster M; EANM Dosimetry Committee . EANM Dosimetry Committee series on standard operational procedures for pre‐therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging. 2008;35:1405–1412.
    1. Hänscheid H, Lassmann M, Luster M, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006;47:648–654.
    1. Kletting P, Schimmel S, Kestler HA, et al. Molecular radiotherapy: the NUKFIT software for calculating the time‐integrated activity coefficient. Med Phys. 2013;40:102504.
    1. Hindorf C, Glatting G, Chiesa C, Lindén O, Flux G; EANM Dosimetry Committee . EANM Dosimetry Committee guidelines for bone marrow and whole‐body dosimetry. Eur J Nucl Med Mol Imaging. 2010;37:1238–1250.
    1. Cristy M, Eckerman K. Specific Absorbed Fractions of Energy at Various Ages from Internal Photons Sources. Oak Ridge, TN: Oak Ridge National Laboratory; ORNL/TM‐8381 V1–V7; 1987.
    1. Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys. 2003;85:294–310.
    1. Stabin MG, Konijnenberg MW. Re‐evaluation of absorbed fractions for photons and electrons in spheres of various sizes. J Nucl Med. 2000;41:149–160.
    1. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer , Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–1214.
    1. Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer. 1998;83:1012–1021.
    1. Hänscheid H, Lassmann M, Luster M, Kloos RT, Reiners C. Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma. Endocr Relat Cancer. 2009;16:1283–1289.
    1. de Keizer B, Hoekstra A, Konijnenberg MW, et al. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid‐stimulating hormone to treat metastatic differentiated thyroid cancer. J Nucl Med. 2004;45:1549–1554.
    1. Watanabe N, Kanegane H, Kinuya S, et al. The radiotoxicity of 131I therapy of thyroid cancer: assessment by micronucleus assay of B lymphocytes. J Nucl Med. 2004;45:608–611.
    1. Monsieurs MA, Thierens HM, van de Wiele CV, et al. Estimation of risk based on biological dosimetry for patients treated with radioiodine. Nucl Med Commun. 1999;20:911–917.
    1. M'Kacher R, Schlumberger M, Legal JD, et al. Biologic dosimetry in thyroid cancer patients after repeated treatments with iodine‐131. J Nucl Med. 1998;39:825–829.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅